Emmanuelle Liaudet-Coopman Selected Research

Cathepsin D

1/2021	A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
5/2020	Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.
1/2019	Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
2/2016	Alteration of cathepsin D trafficking induced by hypoxia and extracellular acidification in MCF-7 breast cancer cells.
9/2015	Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.
12/2012	Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.
2/2011	Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis.
11/2010	Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?
10/2010	Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.
3/2009	Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emmanuelle Liaudet-Coopman Research Topics

Disease

13	Breast Neoplasms (Breast Cancer) 05/2020 - 08/2002
10	Neoplasms (Cancer) 01/2021 - 08/2002
4	Neoplasm Metastasis (Metastasis) 09/2015 - 08/2002
3	Triple Negative Breast Neoplasms 01/2021 - 01/2019
2	Carcinogenesis 09/2015 - 08/2002
2	Starvation 07/2014 - 03/2014
1	Pulmonary Arterial Hypertension 10/2016
1	Hypoxia (Hypoxemia) 02/2016
1	Obesity 10/2009

Drug/Important Bio-Agent (IBA)

15	Cathepsin DIBA 01/2021 - 08/2002
9	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 08/2002
2	Proteins (Proteins, Gene)FDA Link 02/2016 - 07/2014
1	Androgen Receptors (Androgen Receptor)IBA 05/2020
1	Keratin-5 (Keratin 5)IBA 05/2020
1	Estrogen ReceptorsIBA 05/2020
1	Phenobarbital (Luminal)FDA Link 05/2020
1	AntibodiesIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	ProteomeIBA 10/2016
1	EndopeptidasesIBA 02/2016
1	Parathyroid Hormone-Related ProteinIBA 09/2015
1	HLA-B Antigens (HLA-B)IBA 03/2014
1	procathepsin DIBA 12/2012
1	Indicators and Reagents (Reagents)IBA 12/2012
1	Cysteine (L-Cysteine)FDA Link 12/2012
1	Cystatin CIBA 12/2012
1	CathepsinsIBA 12/2012
1	Carrier Proteins (Binding Protein)IBA 11/2010
1	EnzymesIBA 11/2010
1	LipidsIBA 10/2009
1	CaspasesIBA 03/2009
1	Small Interfering RNA (siRNA)IBA 03/2009
1	Cell Surface ReceptorsIBA 06/2006
1	Aspartic Acid ProteasesIBA 01/2005
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 08/2002
1	Complementary DNA (cDNA)IBA 08/2002
1	AgarIBA 08/2002
1	matrigelIBA 08/2002

Therapy/Procedure

3	Therapeutics 01/2021 - 08/2002
2	Adjuvant Chemotherapy 05/2020 - 01/2019
1	Drug Therapy (Chemotherapy) 01/2019
1	Immunotherapy 01/2019